A New Mexico Senate committee has unanimously approved a bipartisan resolution requesting that state officials research the therapeutic potential of psilocybin and explore the creation of a regulatory framework to provide access to the psychedelic.
The Senate Health and Public Affairs Committee voted 7-0 to pass the resolution from Senate Minority Whip Craig Brandt (R) and Sen. Jeff Steinborn (D) on Saturday.
As “memorial” legislation, the bicameral proposal wouldn’t be binding. Rather, it would represent a formal request for the state Department of Health to “study the efficacy of using psilocybin mushrooms for therapeutic treatments and the establishment of a program for psilocybin mushrooms to be used for therapeutic medical treatments.”
The whereas section of the resolution cites various studies supporting the therapeutic benefits of psilocybin for conditions such as major depression and substance misuse, while pointing out that the federal Food and Drug Administration (FDA) has designated the psychedelic as a “breakthrough therapy.”
To that end, the measure states that the health department should look into “necessary statutory or regulatory framework for developing” a state-level psilocybin program.
“This can help people very potentially, and so what we’re trying to do in a bipartisan way is ask the Department of Health to recognize that we want them to get going to start looking at this,” Steinborn said during Saturday’s committee hearing.
The measure “really seeks to expand therapeutic options for New Mexicans,” he said.
Several researchers and advocates testified in favor of the legislation, urging lawmakers to help make New Mexico a leader on psychedelics research at a time of heightened interest into the potential of substances such as psilocybin to address widespread mental health concerns.
Prior to passage, the committee adopted an amendment stipulating that it wants the health department to partner with the University of New Mexico Health Sciences Center on the psilocybin research.
The committee vote comes one year after the House Health and Human Services Committee passed a similar bill that called for the creation of a state body to study the possibility of launching a psilocybin therapy program for certain patients. That measure did not advance further in the 2023 session, however.
A growing number of states are pursuing psychedelics reform legislation this session, with a focus on research and therapeutic access.
—
Marijuana Moment is tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.
Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—
For example, an Alaska Senate panel took testimony last week on a plan that would create a state task force to explore how to legalize and regulate the therapeutic use of psychedelics in the state.
Bipartisan California lawmakers also recently introduced a bill to legalize psychedelic service centers where adults 21 and older could access psilocybin, MDMA, mescaline and DMT in a supervised environment with trained facilitators.
Arizona lawmakers also filed a bill last month that would legalize psilocybin service centers where people could receive the psychedelic in a medically supervised setting.
A Nevada joint legislative committee held a hearing with expert and public testimony on the therapeutic potential of substances like psilocybin last month. Law enforcement representatives also shared their concerns around legalization—but there was notable acknowledgement that some reforms should be enacted, including possible rescheduling.
The Indiana Senate approved a bill this month that would fund clinical research trials into psilocybin-assisted therapy for mental health.
The governor of Massachusetts recently promoted the testimony of activists who spoke in favor of her veterans-focused bill that would, in part, create a psychedelics work group to study the therapeutic potential of substances such as psilocybin.
A New York lawmaker recently introduced a bill that would create a pilot program to provide psilocybin therapy to 10,000 people, focusing on military veterans and first responders, while the legislature also considers broader psychedelics reform.
A Missouri House committee considered a proposal last month that would legalize the medical use of psilocybin in the state and mandate clinical trials exploring the therapeutic potential of the psychedelic.
Delaware Adult-Use Marijuana Shops Will See Delayed Launch Timeline, Top Regulator Says
Read the full article here
